Mapping the Grounds for Mortalities in Acute Myeloid Leukemia Through Registry Analyses: A Retrospective Cohort Study of Children, Adolescents, and Young Adults Patients

• Published in: Journal of clinical medicine research 2024-06, Vol.16 (6), p.310-318
• Main Authors: Elgenidy, Anas, Al-Kurdi, Mohammed Al-Mahdi, Ibrahim, Hoda Atef Abdelsattar, Gad, Eman F, Awad, Ahmed K, Caruana, Rebecca, Diacono, Sheriseane, Sherif, Aya, Elattar, Tasneem, Al-Ghanam, Islam E, Eldmaty, Asmaa M, Abubasheer, Tareq M, Afifi, Ahmed M, Elhoufey, Amira, Dailah, Hamad Ghaleb, Osman, Amira M, Ezzat, Mohamed, Gamal, Doaa Ali, Elmonier, Rady, Hammour, Ahmed El-Sayed, Abougabal, Maged T, Saad, Khaled
• Format: Article
• Language: English
• Subjects: Original
• ISSN: 1918-3003; 1918-3011
• DOI: 10.14740/jocmr5205

Our objective was to identify non-malignant factors that contribute to mortality in children, adolescents and young adults, aiming to improve patient follow-up and reduce mortality rates to achieve better survival outcomes. We analyzed 8,239 acute myeloid leukemia (AML) cases diagnosed between 2000 and 2019 in the USA. Using version 8.4.0.1 of the Surveillance, Epidemiology, and End Results (SEER)*Stat software, we calculated the standardized mortality ratios (SMRs) and 95% confidence intervals (CIs) for each cause of death. Out of the 3,165 deaths observed in the study population, the majority (2,245;70.9%) were attributed to AML itself, followed by non-AML cancers (573; 18.1%) and non-cancerous causes (347; 10.9%). Patients with AML are at a higher risk of developing other types of cancer and granulocyte deficiencies, which increases the risk of death from non-cancerous causes such as infections. Moreover, treatment for AML carries the risk of cardiac problems. AML is commoner in males than females.